GO:0070555 response to interleukin-1: Inflammatory Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070555 response to interleukin-1 describes any cellular or organismal process that changes in state or activity due to an interleukin-1 stimulus.
• Interleukin-1 (IL-1) is a master cytokine of innate immunity and inflammation, with IL-1β and IL-1α as the principal agonists.
• The response to IL-1 involves rapid signaling through the IL-1 receptor (IL-1R1), MYD88, IRAK, TRAF6, NF-κB, and MAPK cascades.
• IL-1 responses shape fever, sleep, metabolic shifts, immune cell activation, and tissue remodeling after injury.
• Dysregulated IL-1 signaling contributes to autoinflammatory diseases, atherosclerosis, arthritis, and adverse cardiac remodeling.
• CRISPR knockout, knock-in, point-mutation, and overexpression models enable causal dissection of IL-1 pathway genes in disease contexts.
Description
Interleukin-1 (IL-1) is one of the most pleiotropic cytokines in immunology, and the Gene Ontology term GO:0070555 response to interleukin-1 captures the full set of cellular and organismal changes triggered by IL-1 stimulation. This process includes rapid signal transduction from the IL-1 receptor, transcriptional reprogramming, secretion of secondary mediators, and systemic responses such as fever and metabolic adaptation. Because IL-1 sits at the interface of innate immunity, tissue repair, and chronic inflammation, researchers across immunology, neuroscience, cardiology, and metabolism study this term to understand both protective and pathogenic outcomes. The response to IL-1 is not a single linear pathway but a network of receptor-proximal events, kinase cascades, and gene expression programs that vary by cell type and context. Consequently, precise experimental models, including CRISPR-engineered cell lines and animals, are essential to assign causality to individual components of the response. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:0070555, its mechanisms, key genes, disease relevance, and modern methods for interrogation.
response to interleukin-1 At A Glance
| GO ID | GO:0070555 |
|---|---|
| GO term | response to interleukin-1 |
| Ontology | biological_process |
| Synonym | response to IL-1 |
| Definition | Any process that results in a change in state or activity of a cell or an organism as a result of an interleukin-1 stimulus. |
| Major function | Mediates cellular and systemic responses to IL-1 family cytokines, including inflammation, fever, and immune activation. |
| Key receptors | IL-1R1, IL-1R2, IL-1RAcP |
| Key signaling nodes | MYD88, IRAK1/4, TRAF6, NF-κB, MAPK |
| Representative stimuli | IL-1α, IL-1β |
What Is GO:0070555?
GO:0070555 response to interleukin-1 is defined by QuickGO as any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-1 stimulus. In practice, this encompasses receptor binding, intracellular signal transduction, changes in gene expression, metabolic shifts, and physiological outputs such as fever or sleep alteration.
Why Is response to interleukin-1 Important in Cell Biology?
GO:0070555 is central to understanding how a single cytokine can orchestrate diverse physiological and pathological outcomes, from host defense and fever to chronic tissue damage. Because IL-1 is a validated drug target in autoinflammatory and cardiovascular diseases, dissecting the response to IL-1 at the gene and pathway level has direct translational value. Moreover, the term provides a structured framework for annotating genes and interpreting omics data in inflammation research.
• IL-1 is a master regulator of innate immunity and inflammation, making GO:0070555 a core process in immunology.
• The response to IL-1 includes fever, sleep modulation, and metabolic changes that affect whole-organism physiology.
• IL-1 signaling drives immune cell activation, including follicular helper and regulatory T cell responses.
• Dysregulated IL-1 responses are implicated in autoinflammatory syndromes, arthritis, and atherosclerosis.
• IL-1 contributes to adverse cardiac remodeling after myocardial infarction through effects on fibroblasts.
• IL-1β-deficient mice show altered inflammatory responses, demonstrating the non-redundant role of this cytokine.
• The pathway is a target of biologics such as anakinra and canakinumab, underscoring clinical relevance.
• Understanding GO:0070555 aids interpretation of transcriptomic and proteomic data in inflammatory disease models.
• CRISPR-based models allow causal testing of IL-1 pathway genes in relevant cell types.
What Happens During response to interleukin-1?
Receptor engagement and proximal signaling
In simple terms: IL-1 binds to its receptor on the cell surface, which switches on the first set of signaling proteins inside the cell.
The response begins when IL-1α or IL-1β binds to the type I IL-1 receptor (IL-1R1), recruiting the co-receptor IL-1RAcP and forming a signaling complex. This complex recruits the adaptor MYD88, which in turn assembles IRAK kinases and TRAF6, initiating downstream cascades. The decoy receptor IL-1R2 and the antagonist IL-1Ra can modulate this step, providing negative regulation.
Activation of NF-κB and MAPK pathways
In simple terms: The signal travels to the nucleus and other cellular machinery, turning on inflammatory genes and stress responses.
TRAF6 ubiquitination leads to activation of TAK1, which phosphorylates IKK and MAPK kinases, resulting in NF-κB nuclear translocation and AP-1 activation. These transcription factors induce expression of cytokines, chemokines, adhesion molecules, and enzymes such as COX-2. The MAPK arm also regulates mRNA stability and translation of inflammatory mediators.
Transcriptional and post-transcriptional reprogramming
In simple terms: The cell changes which genes are made into proteins, amplifying or dampening the inflammatory response.
NF-κB and MAPK-driven transcription rapidly changes the cell's gene expression profile, including induction of IL-6, TNF, and IL-1 itself. Post-transcriptional mechanisms, including mRNA stability and microRNA regulation, fine-tune the output. This reprogramming underlies functional changes such as immune cell activation and fibroblast proliferation.
Systemic and physiological outputs
In simple terms: The response extends beyond single cells to affect the whole body, causing fever, sleep changes, and metabolic shifts.
IL-1 acts on the central nervous system to modulate sleep and fever, and it induces acute-phase protein production in the liver. Centrally and peripherally mediated metabolic responses include altered glucose and lipid metabolism. These systemic effects are part of the organism-level response to IL-1.
Resolution and negative feedback
In simple terms: The cell has brakes to stop the response so inflammation does not become harmful.
Negative regulators such as IL-1Ra, IL-1R2, and SOCS proteins limit the duration and intensity of signaling. Failure of these brakes can lead to chronic inflammation and disease. Understanding resolution mechanisms is key to therapeutic targeting of GO:0070555.
Key Genes Involved in GO:0070555 response to interleukin-1
The following genes and proteins are central to the response to interleukin-1, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL1B | Principal agonist cytokine IL-1β | Key mediator of inflammation; knockout mice show altered responses |
| IL1A | Agonist cytokine IL-1α | Tissue-derived alarmin; studied in sterile inflammation |
| IL1R1 | Type I IL-1 receptor | Initiates signaling; target for blocking antibodies |
| IL1R2 | Decoy receptor | Negative regulator of IL-1 signaling |
| IL1RN | IL-1 receptor antagonist | Endogenous inhibitor; mutations cause autoinflammatory disease |
| MYD88 | Adaptor protein | Central node in IL-1R signaling |
| IRAK1 | Kinase | Recruited to receptor complex; regulates NF-κB |
| IRAK4 | Kinase | Essential for IL-1R signaling; drug target |
| TRAF6 | E3 ubiquitin ligase | Activates TAK1 and downstream pathways |
| NFKB1 | Transcription factor | Drives inflammatory gene expression |
| MAPK1 | Kinase | Regulates AP-1 and inflammatory gene expression |
| IL6 | Cytokine | Induced by IL-1; amplifies inflammation |
| TNF | Cytokine | Induced by IL-1; synergizes in inflammation |
| PTGS2 | COX-2 enzyme | Induced by IL-1; produces prostaglandins |
| CXCL8 | Chemokine | Recruits neutrophils; induced by IL-1 |
| SOCS1 | Negative regulator | Limits cytokine signaling |
| FOXP3 | Transcription factor | Regulates Treg responses to IL-1 |
How Is response to interleukin-1 Regulated?
The response to interleukin-1 is tightly regulated at multiple levels. Negative regulators include IL-1Ra, which competes for receptor binding, and the decoy receptor IL-1R2, which sequesters IL-1. Intracellular brakes such as SOCS proteins and deubiquitinases attenuate NF-κB and MAPK signaling. Post-transcriptional mechanisms, including mRNA stability and microRNAs, further modulate the intensity and duration of the response. Dysregulation of these control points can lead to chronic inflammatory diseases.
response to interleukin-1 and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL1B | Autoinflammatory fever syndromes | IL1B knockout mice |
| IL1RN | DIRA (deficiency of IL-1 receptor antagonist) | IL1RN knock-in mutation in cell lines |
| IL1R1 | Rheumatoid arthritis | IL1R1 knockout or knockdown cells |
| NLRP3 | Cryopyrin-associated periodic syndromes | NLRP3 point-mutation knock-in |
| PTGS2 | Inflammation and pain | PTGS2 overexpression in fibroblasts |
Autoinflammatory and autoimmune diseases
Gain-of-function mutations in NLRP3 or loss-of-function in IL1RN lead to excessive IL-1β activity and autoinflammatory syndromes. IL-1 also contributes to rheumatoid arthritis and other autoimmune conditions by promoting cytokine and chemokine production. Targeting IL-1 signaling with biologics has proven effective in these diseases.
Cardiovascular disease and post-infarction remodeling
IL-1 affects cardiac fibroblasts, promoting matrix remodeling and adverse outcomes after myocardial infarction. Clinical trials of IL-1β inhibition have shown reduced cardiovascular events, highlighting the importance of this pathway. Experimental models using IL-1β knockout or receptor blockade are used to study these effects.
Neuroinflammation and sleep disorders
IL-1 is involved in sleep regulation and responses to sleep deprivation, acting on the central nervous system. Excessive IL-1 signaling contributes to neuroinflammation in neurodegenerative conditions. Animal models with IL-1β deficiency or receptor antagonism help dissect these roles.
Metabolic and systemic responses
IL-1 mediates centrally and peripherally regulated metabolic changes, including fever and altered glucose metabolism. Chronic IL-1 activity is linked to insulin resistance and metabolic syndrome. Studying these systemic effects requires integrated physiological models.
From response to interleukin-1-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL1B drive inflammatory cytokine production? | IL1B knockout cell line (e.g., THP-1) |
| What is the effect of a disease-associated IL1RN mutation? | IL1RN point-mutation knock-in |
| Can IL-1 receptor signaling be tracked in live cells? | IL1R1 tagged knock-in (e.g., GFP) |
| Does overexpression of IL1B mimic chronic inflammation? | IL1B overexpression in fibroblasts |
| Which genes are essential for IL-1 response? | Genome-wide CRISPR knockout library screening |
| How does IL-1 affect T cell differentiation? | FOXP3 reporter knock-in in T cells |
How to Study the response to interleukin-1 Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify IL-1-responsive genes |
| Phosphoproteomics | Kinase activity and signaling nodes | Map IL-1R proximal signaling |
| CRISPR knockout screen | Genes required for IL-1 response | Discover novel pathway components |
| NF-κB reporter assay | NF-κB transcriptional activity | Quantify IL-1 signaling strength |
| ELISA | Cytokine secretion (e.g., IL-6, TNF) | Measure functional output |
| Live-cell imaging | Protein localization and dynamics | Track IL-1R trafficking |
| Flow cytometry | Immune cell activation markers | Assess T cell responses to IL-1 |
Transcriptomic profiling (RNA-seq)
RNA sequencing after IL-1 stimulation reveals the global gene expression changes that define GO:0070555, including induction of cytokines, chemokines, and adhesion molecules. This method is widely used to identify novel IL-1-responsive genes and to compare responses across cell types.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based proteomics can quantify changes in protein abundance and phosphorylation after IL-1 treatment, mapping signaling nodes such as IRAK and TAK1. These approaches help identify feedback regulators and drug targets.
CRISPR screening
Pooled CRISPR knockout screens enable unbiased discovery of genes required for IL-1-induced phenotypes, such as NF-κB activation or cytokine secretion. Hits can be validated individually using knockout cell lines.
Reporter assays and imaging
NF-κB or MAPK reporter cell lines and live-cell imaging allow real-time monitoring of IL-1 signaling dynamics. Tagged knock-in of pathway components enables visualization of protein localization and interactions.
How CRISPR Can Be Used to Study GO:0070555 response to interleukin-1
Knockout
CRISPR knockout of IL1B, IL1R1, MYD88, or IRAK4 in cell lines such as THP-1 or primary fibroblasts abolishes specific arms of the IL-1 response, enabling causal assignment. Knockout mice for Il1b show altered inflammatory responses, validating the approach.
Point Mutation
Introducing disease-associated point mutations, such as those in IL1RN or NLRP3, into cell lines via CRISPR base editing or HDR allows study of gain- or loss-of-function effects on IL-1 signaling. These models are valuable for testing targeted therapies.
Knock-in
Tagged knock-in of IL1R1 or MYD88 with fluorescent or affinity tags enables real-time tracking of receptor complex assembly and trafficking. Reporter knock-in of NF-κB response elements can quantify pathway activation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of IL1B or constitutively active IRAK4 can mimic chronic IL-1 signaling, useful for modeling inflammatory diseases. Overexpression in cardiac fibroblasts recapitulates aspects of post-infarction remodeling.
How EDITGENE Supports response to interleukin-1 Research
Researchers studying response to interleukin-1-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with its activation. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes within GO:0070555.
Contact EDITGENE today to design your custom CRISPR model for response to interleukin-1 research.
Frequently Asked Questions About response to interleukin-1
What is GO:0070555 response to interleukin-1?
GO:0070555 is a Gene Ontology biological process term describing any cellular or organismal change caused by an interleukin-1 stimulus, including signaling, gene expression, and physiological responses.
What genes are involved in response to interleukin-1?
Key genes include IL1B, IL1A, IL1R1, IL1R2, IL1RN, MYD88, IRAK1, IRAK4, TRAF6, NFKB1, and MAPK1, among others.
How does IL-1 signaling work?
IL-1 binds to IL-1R1, recruiting MYD88 and IRAK kinases, which activate NF-κB and MAPK pathways to induce inflammatory gene expression.
What diseases are associated with IL-1 signaling?
Dysregulated IL-1 signaling is linked to autoinflammatory syndromes, rheumatoid arthritis, atherosclerosis, and adverse cardiac remodeling.
What is the role of IL-1 in fever and sleep?
IL-1 acts on the central nervous system to modulate fever and sleep, and is involved in responses to sleep deprivation.
How can I study response to interleukin-1 in the lab?
Common methods include RNA-seq, phosphoproteomics, CRISPR screens, reporter assays, and ELISA for cytokine secretion.
What CRISPR models are available for IL-1 pathway genes?
Knockout, point-mutation knock-in, tagged knock-in, and overexpression models can be generated for genes such as IL1B, IL1R1, and MYD88.
What is the difference between IL-1α and IL-1β?
Both are agonists, but IL-1β is primarily secreted and systemic, while IL-1α is often membrane-bound or released during cell damage.
How is IL-1 signaling negatively regulated?
Negative regulators include IL-1Ra, IL-1R2 decoy receptor, SOCS proteins, and deubiquitinases that attenuate NF-κB and MAPK signaling.
Why is IL-1 a drug target?
IL-1 drives multiple inflammatory diseases, and biologics such as anakinra and canakinumab have shown clinical benefit, validating the pathway as a therapeutic target.
Conclusion
GO:0070555 response to interleukin-1 is a fundamental biological process that bridges innate immunity, systemic physiology, and disease. Its complexity demands precise experimental models to dissect causal genes and signaling nodes. By integrating QuickGO definitions with verified literature, this article provides a framework for researchers to study IL-1 responses using modern CRISPR and omics technologies. EDITGENE offers end-to-end solutions to accelerate discoveries in this critical pathway.
References
- 1. Dinarello CA. 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases.. Blood 117(14):3720-32 PMID: 21304099
- 2. Dinarello CA. 2009. Immunological and inflammatory functions of the interleukin-1 family.. Annu Rev Immunol 27:519-50 PMID: 19302047
- 3. Ritvo PG et al.. 2019. Interleukin-1 in the Response of Follicular Helper and Follicular Regulatory T Cells.. Front Immunol 10:250 PMID: 30873158
- 4. Bankers-Fulbright JL et al.. 1996. Interleukin-1 signal transduction.. Life Sci 59(2):61-83 PMID: 8699924
- 5. Turner NA. 2014. Effects of interleukin-1 on cardiac fibroblast function: relevance to post-myocardial infarction remodelling.. Vascul Pharmacol 60(1):1-7 PMID: 23806284
- 6. Fantuzzi G et al.. 1996. The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice.. J Leukoc Biol 59(4):489-93 PMID: 8613694
- 7. Opp MR et al.. 1994. Interleukin-1 is involved in responses to sleep deprivation in the rabbit.. Brain Res 639(1):57-65 PMID: 8180839
- 8. Hill AG et al.. 1997. Metabolic responses to interleukin-1: centrally and peripherally mediated.. Ann Surg 225(3):246-51 PMID: 9060579
